APOE Insight + Amyloid Balance Bundle-LOR Diagnostics Kit - Test of the Month:
Note: This is a test kit that will be mailed to you. It requires a blood draw. It is your responsibility to arrange the blood draw for your kit and payment of your specimen collection.
Fasting Required: No
Lab: LOR Diagnostics
Specimen: Blood
Results: Average processing time 5 business days
Note: Result turnaround times are an estimate and are not guaranteed. Our reference lab may need additional time due to weather, holidays, confirmation/repeat testing, or equipment maintenance.
Description: LOR Diagnostics is committed to helping support earlier awareness of cognitive health through advanced blood-based Alzheimer’s biomarker testing. Their testing options are designed to provide additional insight into potential Alzheimer’s-related changes using innovative laboratory technology and a simple blood sample.
Their advanced cognitive health testing is designed to provide additional insight into Alzheimer’s-associated biomarkers and genetic risk factors that may be associated with cognitive health changes over time.
This testing may be beneficial for individuals who:
- Have a family history of Alzheimer’s disease
- Are experiencing memory or cognitive concerns
- Want additional information about cognitive health and risk factors
- Are interested in proactive health and wellness insights
Testing Included: Amyloid Balance is a blood-based Alzheimer’s biomarker test that evaluates pTau217 and Beta-Amyloid 1-42 and provides a calculated ratio. By evaluating both biomarkers together, Amyloid Balance provides a more comprehensive picture of the patient’s Alzheimer’s-related biomarker profile. These biomarkers are associated with Alzheimer’s disease-related amyloid pathology. The test can provide healthcare providers with additional biological information to consider as part of a broader clinical evaluation of patients with cognitive concerns.
APOE Insight evaluates specific genetic variants of the APOE gene, including APOE2, APOE3, and APOE4. Certain APOE variants, particularly APOE4, are associated with an increased risk of developing Alzheimer’s disease. APOE testing does not diagnose Alzheimer’s disease or determine whether an individual will develop the disease, but it can provide additional information about an individual’s genetic risk profile.